---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059152"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:45:31.323162+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CV Sciences Q1 2024 revenue $4.0M, gross margin 46.3%, operating loss $0.6M

## Summary
- Revenue $4.0M, down 4% YoY from $4.1M, up sequentially from $3.8M in Q4 2023.
- Gross margin 46.3%, best in 12 quarters, up from 43.0% in Q1 2023.
- Operating loss $0.6M vs operating income $5.8M in Q1 2023 (due to reversal of accrued payroll tax of $6.2M).
- Adjusted EBITDA negative $0.5M vs negative $0.2M in Q1 2023; cash $0.7M down from $1.3M.
- Acquired Elevated Softgels, a Colorado softgel and tincture manufacturer; no deal terms disclosed.

## SEC filing metadata
- accession: 0000950170-24-059152
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000095017024059152/0000950170-24-059152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000095017024059152/cvsi-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059152
- JSON: https://secwatch.observer/filing/0000950170-24-059152.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059152.txt

## Key facts
- Earnings Releases
  CV Sciences, Inc. reported for the quarter ended March 31, 2024 results: revenue $4.0 million.
  - Period: for the quarter ended March 31, 2024
  - Revenue: $4.0 million
  - Result: reported results
  source text: and products, today announced its financial results for the quarter ended March 31, 2024. First Quarter 2024 and Recent Financial and Operating Highlights • Generated revenue of $4.0 million for first quarter 2024 compared to $4.1 million for the first quarter 2023 and a sequential improvement from $3.8 million for the fourth quarter 2023; • Recognized gross margin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1510964/000095017024059152/0000950170-24-059152-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.